HUTCHMED (HCM) Projected to Announce Quarterly Earnings on Thursday

HUTCHMED (NASDAQ:HCM) is expected to be announcing its H1 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of $0.1450 per share and revenue of $304.1560 million for the quarter. Investors can find conference call details on the company’s upcoming H1 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

HUTCHMED Trading Up 1.0%

HUTCHMED stock opened at $11.12 on Tuesday. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.05. HUTCHMED has a 12-month low of $9.77 and a 12-month high of $19.50. The firm’s fifty day moving average is $11.07 and its 200 day moving average is $13.31.

Analyst Upgrades and Downgrades

HCM has been the subject of a number of research reports. The Goldman Sachs Group reduced their price target on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday. Morgan Stanley set a $13.60 price objective on shares of HUTCHMED in a report on Thursday, May 28th. Weiss Ratings raised shares of HUTCHMED from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, July 17th. Finally, Bank of America reduced their target price on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, HUTCHMED currently has an average rating of “Hold” and a consensus target price of $14.87.

Institutional Trading of HUTCHMED

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its stake in shares of HUTCHMED by 8.5% in the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after buying an additional 7,342 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after acquiring an additional 124,771 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares during the last quarter. Bank of America Corp DE lifted its position in HUTCHMED by 17.3% in the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after acquiring an additional 3,035 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in HUTCHMED by 19.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock valued at $377,000 after acquiring an additional 4,116 shares in the last quarter. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.